Ind-Swift posts strong Q2 FY27 growth; FY27 revenue outlook is above 50%

Management guided margin improvementMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.2%Reaction day

₹347.80

prior close

₹357.60

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+2.2%+5.0% vs market

Pharmaceuticals peers, median of 173sector+0.8%+6.4% vs sector

On the reaction day the stock moved 5.0 pts more than Nifty Microcap 250 and 6.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.5

15m

+1.0

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.2+2.2+5.0+0.8+6.4

Next day

+2.6+3.3-0.7+1.6+1.0

-0.4pendingpending+1.5-1.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue was ₹242.49 crore, up 25.18% QoQ, operating EBITDA ₹42.33 crore at an 18.02% margin, and net profit ₹31.03 crore. H1 revenue rose 31.83% to ₹436.20 crore; operating EBITDA reached ₹75.65 crore, 4.5 times year ago. Management expects FY27 revenue growth above 50%, a 20-25% medium-term CAGR, FY30 revenue above ₹1,500 crore, and 200-300 basis points margin expansion. The ₹250 crore capex plan is internally funded.

Likely market impact

Positive: faster revenue, stronger margins and a debt-free, self-funded growth plan support shareholders, though execution and upgrade risks remain.